Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function

被引:9
作者
German, P. [1 ]
Bai, S. [1 ]
Liu, X-D [1 ]
Sun, M. [1 ]
Zhou, L. [1 ]
Kalra, S. [1 ]
Zhang, X. [1 ]
Minelli, R. [2 ]
Scott, K. L. [2 ]
Mills, G. B. [3 ]
Jonasch, E. [1 ]
Ding, Z. [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
关键词
PROTEIN-KINASE CK2; TUMOR-SUPPRESSOR PROTEIN; GENE ALTERATIONS; IN-VIVO; MUTATIONS; PRODUCT; COMPLEX; BINDING; HIF; IDENTIFICATION;
D O I
10.1038/onc.2016.40
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Loss of von Hippel Lindau (VHL) protein function is a key driver of VHL diseases, including sporadic and inherited clear cell renal cell carcinoma. Modulation of the proteostasis of VHL, especially missense point-mutated VHL, is a promising approach to augmenting VHL levels and function. VHL proteostasis is regulated by multiple mechanisms including folding, chaperone binding, complex formation and phosphorylation. Nevertheless, many details underlying the regulations of VHL proteostasis are unknown. VHL is expressed as two variants, VHL30 and VHL19. Furthermore, the long-form variant of VHL was often detected as multiple bands by western blotting. However, how these multiple species of VHL are generated and whether the process regulates VHL proteostasis and function are unknown. We hypothesized that the two major species are generated by VHL protein cleavage, and the cleavage regulates VHL proteostasis and subsequent function. We characterized VHL species using genetical and pharmacological approaches and showed that VHL was first cleaved at the N-terminus by chymotrypsin C before being directed for proteasomal degradation. Casein kinase 2-mediated phosphorylation at VHL N-terminus was required for the cleavage. Furthermore, inhibition of cleavage stabilized VHL protein and thereby promoted HIF downregulation. Our study reveals a novel mechanism regulating VHL proteostasis and function, which is significant for identifying new drug targets and developing new therapeutic approaches targeting VHL deficiency in VHL diseases.
引用
收藏
页码:4973 / 4980
页数:8
相关论文
共 33 条
[1]   Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1α mediated transcription [J].
Ampofo, Emmanuel ;
Kietzmann, Thomas ;
Zimmer, Andreas ;
Jakupovic, Mirza ;
Montenarh, Mathias ;
Goetz, Claudia .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2010, 42 (10) :1729-1735
[2]   Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer [J].
Banks, RE ;
Tirukonda, P ;
Taylor, C ;
Hornigold, N ;
Astuti, D ;
Cohen, D ;
Maher, ER ;
Stanley, AJ ;
Harnden, P ;
Joyce, A ;
Knowles, M ;
Selby, PJ .
CANCER RESEARCH, 2006, 66 (04) :2000-2011
[3]   A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners [J].
Ding, Zhiyong ;
Liang, Jiyong ;
Lu, Yiling ;
Yu, Qinghua ;
Zhou Songyang ;
Lin, Shiaw-Yih ;
Mills, Gordon B. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (41) :15014-15019
[4]   Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein [J].
Ding, Zhiyong ;
German, Peter ;
Bai, Shanshan ;
Reddy, A. Srinivas ;
Liu, Xian-De ;
Sun, Mianen ;
Zhou, Lijun ;
Chen, Xiaohua ;
Zhao, Xiaobei ;
Wu, Chengbiao ;
Zhang, Shuxing ;
Mills, Gordon B. ;
Jonasch, Eric .
CANCER RESEARCH, 2014, 74 (11) :3127-3136
[5]   Agents That Stabilize Mutated von Hippel-Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis [J].
Ding, Zhiyong ;
German, Peter ;
Bai, Shanshan ;
Feng, Zhehui ;
Gao, Meng ;
Si, Wendy ;
Sobieski, Mary M. ;
Stephan, Clifford C. ;
Mills, Gordon B. ;
Jonasch, Eric .
JOURNAL OF BIOMOLECULAR SCREENING, 2012, 17 (05) :572-580
[6]   CHARACTERIZATION OF THE VHL TUMOR-SUPPRESSOR GENE-PRODUCT - LOCALIZATION, COMPLEX-FORMATION, AND THE EFFECT OF NATURAL INACTIVATING MUTATIONS [J].
DUAN, DR ;
HUMPHREY, JS ;
CHEN, DYT ;
WENG, YK ;
SUKEGAWA, J ;
LEE, S ;
GNARRA, JR ;
LINEHAN, WM ;
KLAUSNER, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (14) :6459-6463
[7]   Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding [J].
Feldman, DE ;
Spiess, C ;
Howard, DE ;
Frydman, J .
MOLECULAR CELL, 2003, 12 (05) :1213-1224
[8]   Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC [J].
Feldman, DE ;
Thulasiraman, V ;
Ferreyra, RG ;
Frydman, J .
MOLECULAR CELL, 1999, 4 (06) :1051-1061
[9]   Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J].
Gerlinger, Marco ;
Rowan, Andrew J. ;
Horswell, Stuart ;
Larkin, James ;
Endesfelder, David ;
Gronroos, Eva ;
Martinez, Pierre ;
Matthews, Nicholas ;
Stewart, Aengus ;
Tarpey, Patrick ;
Varela, Ignacio ;
Phillimore, Benjamin ;
Begum, Sharmin ;
McDonald, Neil Q. ;
Butler, Adam ;
Jones, David ;
Raine, Keiran ;
Latimer, Calli ;
Santos, Claudio R. ;
Nohadani, Mahrokh ;
Eklund, Aron C. ;
Spencer-Dene, Bradley ;
Clark, Graham ;
Pickering, Lisa ;
Stamp, Gordon ;
Gore, Martin ;
Szallasi, Zoltan ;
Downward, Julian ;
Futreal, P. Andrew ;
Swanton, Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :883-892
[10]   VHL, the story of a tumour suppressor gene [J].
Gossage, Lucy ;
Eisen, Tim ;
Maher, Eamonn R. .
NATURE REVIEWS CANCER, 2015, 15 (01) :55-64